Seven Eight Capital’s Ventyx Biosciences VTYX Stock Holding History

Seven Eight Capital’s Portfolio VTYX Stock Details VTYX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-9,184	Closed	-$301K	–	758
2023 Q2	$301K	Buy	+9,184	New	+$317K	0.05%	394

Other funds holding VTYX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Holocene Advisors New York $41.5B AUM 42.97% 1-Year Est. Return

Seven Eight Capital's VTYX Position: Q3 2023 in Review

Seven Eight Capital sold out of Ventyx Biosciences (VTYX) in Q3 2023, closing a stake of 9,184 shares — an estimated $301K sold.

Seven Eight Capital first reported a position in VTYX in Q2 2023 and held it in 1 quarter. The position peaked at $301K in Q2 2023. 138 funds tracked by Wall St. Rank hold VTYX as of Q3 2023.

Seven Eight Capital reported no remaining Ventyx Biosciences position as of Q3 2023 after selling out during the quarter.
Seven Eight Capital sold 9,184 Ventyx Biosciences shares in Q3 2023, an estimated $301K.
Seven Eight Capital first reported a position in Ventyx Biosciences in Q2 2023 and held it in 1 quarter.
Seven Eight Capital's Ventyx Biosciences position peaked at $301K in Q2 2023.
138 funds tracked by Wall St. Rank held Ventyx Biosciences as of Q3 2023.

Based on Seven Eight Capital's 13F filing for Q3 2023, filed 14 Nov 2023.